Evidence for T-large granular lymphocyte-mediated neutropenia in Rituximab-treated lymphoma patients: report of two cases

Leuk Res. 2002 Jun;26(6):597-600. doi: 10.1016/s0145-2126(01)00183-7.

Abstract

We report two cases with B cell malignancies (case #1: refractory mantle cell lymphoma; case #2: lymphocyte predominant Hodgkin's disease (LPHD)) who developed neutropenia post-Rituximab therapy in a setting of significant infiltration of the peripheral blood (PB) and bone marrow (BM) by T cells with an immunophenotype of large granular lymphocytes. Possible pathogenetic mechanisms are discussed.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / adverse effects*
  • Antibodies, Monoclonal, Murine-Derived
  • Antigens, CD / analysis
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / adverse effects*
  • Humans
  • Immunophenotyping
  • Lymphoma, B-Cell / complications
  • Lymphoma, B-Cell / drug therapy*
  • Male
  • Neutropenia / chemically induced*
  • Neutropenia / etiology
  • Rituximab
  • T-Lymphocytes / drug effects
  • T-Lymphocytes / immunology
  • T-Lymphocytes / pathology*

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Antigens, CD
  • Antineoplastic Agents
  • Rituximab